TSRL rebrands as TSRLabs amid growth push

The Ann Arbor preclinical CRO has changed its name, visual identity and website as it marks its 40th anniversary and prepares for its next phase of expansion. TSRLabs is also building on proprietary drug delivery work, new funding momentum and a wider scientific footprint.

Why it matters: - TSRLabs is signaling a broader, more modern identity as it tries to translate 40 years of scientific work into its next growth phase. - The rebrand aims to preserve long-standing client recognition while highlighting the company’s expanding research capabilities and drug delivery technologies. - The company is also positioning its Ann Arbor headquarters as a hub for both established drug development work and emerging life sciences firms.

What happened: - TSRL, Inc. announced it is rebranding as TSRLabs. - The company unveiled a new name, visual identity, logo and redesigned website. - The announcement came during TSRLabs’ 40th anniversary year. - TSRLabs is based in Ann Arbor, Michigan. - The company’s website is More information.

The details: - TSRLabs is a preclinical contract research organization focused on testing services and early-stage development strategy. - The company was founded in 1986 as Therapeutic Systems Research Laboratories. - TSRLabs supports biotechnology, pharmaceutical, academic and government partners. - Core work includes formulation development, bioanalysis, PK/ADME, toxicology, strategic consulting and drug delivery technology. - The new brand keeps “TSRL” at the center of the name, with “Labs” meant to emphasize the company’s scientific and laboratory expertise. - The redesigned website is intended to show the company’s current scope and leave room for new capabilities. - TSRLabs says the site presents its scientific expertise, services, technologies and research more clearly. - Dr. Elke Lipka, president and CEO, said the company used the 40-year milestone to think about what comes next. - Lipka said TSRLabs has stayed independent and grown through major changes in drug development and the broader economy. - Dawn Reyna, chief operations officer, said the new identity does not change how TSRLabs operates. - TSRLabs is a woman-owned preclinical CRO. - The company also describes itself as offering formulation development, bioanalysis, exploratory toxicology and pharmacokinetic strategies to guide human dosing schedules.

Between the lines: - The rebrand is doing two jobs at once: protecting an established reputation and making the company look ready for a broader market. - The emphasis on “Labs” and on collaborative science suggests TSRLabs wants to be seen less as a legacy service provider and more as an innovation partner. - The company’s focus on non-dilutive funding and proprietary technology points to a strategy that blends service revenue with scientific platform development. - By opening its headquarters to emerging life sciences organizations, TSRLabs is trying to create an ecosystem around its own research operations.

What's next: - TSRLabs plans to keep expanding its preclinical research capabilities. - The company expects to advance its proprietary drug delivery technologies. - TSRLabs also plans to keep investing in scientists and emerging talent. - The company will continue developing its Microneedle Array Patch technology across multiple therapeutic applications. - TSRLabs says it will keep opening its Ann Arbor headquarters to new life sciences organizations as it grows. - The company will continue using the new website as the public-facing home for its brand and services.

The bottom line: - TSRLabs is using its 40th year to reset the brand around growth, science and long-term relevance without abandoning the name recognition it has built over decades.